New drug target for inflammatory disease is all the RAGE

New drug target for inflammatory disease is all the RAGE
Credit: Mary Ann Liebert, Inc., publishers

Researchers have shown that Receptor for Advanced Glycation End Products (RAGE) helps to regulate a key signaling pathway known to promote both acute and chronic inflammation. The development of therapeutic drugs targeted to RAGE could be used to treat a range of inflammatory diseases such as asthma, infection, atherosclerosis, and arthritis, as described in an article in DNA and Cell Biology.

In "Receptor for Advanced Glycation End Products (RAGE) Regulates Leukotriene B4 Receptor 1 Signaling," authors Takako Ichiki Tomoaki Koga, and Takehiko Yokomizo, Juntendo University School of Medicine, Tokyo, and Kumamoto University, Kumamoto, Japan, report how they observed that RAGE binds to the leukotriene B4 receptor 1 (BLT1) receptor. This interaction between RAGE and BLT1 modifies LTB4-BLT1 signaling, which modulates the inflammatory response through its effects on cell migration.

"RAGE is an alarmin, a molecule that alerts the host of potential risks and challenges. It is induced in or diseases and promotes more inflammation," says Carol Shoshkes Reiss, PhD, Editor-in-Chief, of DNA and Cell Biology and Professor, Departments of Biology and Neural Science, and Global Public Health at New York University, NY. "By developing new drugs to block the interaction of RAGE with its receptor, in the future, there may be treatments of some aspects of these diseases."


Explore further

The beta-1 adrenergic receptor and RAGE work together to break hearts

More information: Takako Ichiki et al, Receptor for Advanced Glycation End Products Regulates Leukotriene BReceptor 1 Signaling, DNA and Cell Biology (2016). DOI: 10.1089/dna.2016.3552
Citation: New drug target for inflammatory disease is all the RAGE (2016, December 21) retrieved 30 November 2020 from https://medicalxpress.com/news/2016-12-drug-inflammatory-disease-rage.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments